Teleflex Announces First Insertion of ARROW® JACC™ Catheter with Chlorag+ard® Technology
Teleflex Announces First Insertion of ARROW®JACC™ Catheterwith Chlorag+ard®Technology
LIMERICK, Pa.--(BUSINESS WIRE)-- Teleflex Incorporated (NYS: TFX) , a leading global provider of medical devices for critical care and surgery, has announced the first insertion of the new ARROW® JACC™ Catheter with Chlorag+ard® Technology.
The ARROW JACC (Jugular Axillo-subclavian Central Catheter) Catheter with Chlorag+ard Technology is a long-term, small bore antimicrobial and antithrombogenic catheter that gives clinicians a single, less-invasive option for critically ill patients for the duration of their therapy. This catheter, which received FDA clearance in November 2012, is designed specifically for the non-physician, Vascular Access Specialist.
The placing of central venous catheters by non-physician inserters is an emerging trend within healthcare. These Vascular Specialists are driving best practices such as the use of antimicrobial catheters, ultrasound and maximal barrier precautions to offset the high-demand and workload of physicians, who have traditionally placed central lines. To date, Teleflex Incorporated and its ARROW® Vascular Division have supported clinicians in expanding their scope of practice to include central venous catheter insertion in more than forty states.
"The ARROW JACC Catheter with Chlorag+ard Technology has been designed because every patient deserves the right to zero complications," states Paul Molloy, President of the Vascular Division. "The ARROWJACC Catheter is another example of how we continue to innovate and bring products to market that satisfy clinical needs as well as facilitate positive changes we see emerging in the vascular access space."
The ARROW JACC Catheter employs Chlorag+ard Technology as a weapon against infection and thrombosis for up to 30 days. Approximately 80,000 ICU catheter-related bloodstream infections occur each year in the United States resulting in an estimated 28,000 deaths at a cost of $2.3 billion.1 The ARROW JACC Catheter with Chlorag+ard Technology will enable caregivers to effectively and economically care for millions of critically ill patients.
About Teleflex Incorporated
Teleflex is a leading global provider of specialty medical devices for a range of procedures in critical care and surgery. Our mission is to provide solutions that enable healthcare providers to improve outcomes and enhance patient and provider safety. Headquartered in Limerick, PA, Teleflex employs approximately 11,600 people worldwide and serves healthcare providers in more than 140 countries. Additional information about Teleflex can be obtained from the company's website at teleflex.com.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.
Teleflex, Arrow, Chlorag+ard and JACC are trademarks or registered trademarks of Teleflex Incorporated or its affiliates.
© 2013 Teleflex Incorporated. All rights reserved. 2013-1999
1. Pronovost P, Needham D, Berenholtz S, et al. An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med 2006;355(26):2725.
Treasurer and Vice President, Investor Relations
KEYWORDS: United States North America Pennsylvania
The article Teleflex Announces First Insertion of ARROW® JACC™ Catheter with Chlorag+ard® Technology originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.